用Risankizumab治疗活跃牛皮关节炎的肠炎和牙炎解决:随机KEEPsAKE 1和2试验的综合分析
Shawn G Kwatra1, Saakshi Khattri2, Ahmad Z Amin3
1Department of Dermatology, John Hopkins University School of Medicine, 601 N Caroline St, 8th Floor, Baltimore, MD, 21287, USA. kwatra.shawn@gmail.com.
Dermatology and therapy
|May 13, 2024
概括
在牛皮关节炎患者中,risankizumab有效地解决了肠炎和牙炎,显著改善了疼痛,残疾和疲劳. 这些积极的结果持续了52周.
科学领域:
- 类风湿病学 类风湿病学
- 免疫学 免疫学 免疫学
- 临床试验 临床试验
背景情况:
- 肠炎和牙炎是牛皮关节炎 (PsA) 活动的关键指标,对生活质量产生负面影响.
- 作为IL-23抗剂的瑞桑基祖马布已在治疗PsA方面表现出有效性,包括对肠炎/牙炎患者的治疗.
研究的目的:
- 评价瑞桑基祖马布在实现PSA患者肠炎和/或牙炎完全消失的疗效.
- 为了评估患者报告结果的改善,包括疼痛,残疾和疲劳,与risankizumab治疗.
主要方法:
- 对KEEPsAKE 1和KEEPsAKE 2试验的后期分析,这些试验涉及PSA患者的基线肠炎和/或手指炎.
- 通过对肠炎/牙炎的解消和在24周和52周患者报告的结果中实现临床重要差异最小 (MCID) 来评估有效性.
主要成果:
- 与安慰剂相比,risankizumab在第24周显示了与安慰剂相比,炎/甲状腺炎解决率显著更高.
- 到第52周,risankizumab在55.0%的患者 (肠炎),76.1%的患者 (牙炎) 和52.3%的患者 (两者) 中实现了完全的恢复.
- 接受瑞桑基祖马布治疗的患者在疼痛,残疾和疲劳方面也有显著改善,持续到第52周.
结论:
- 与安慰剂相比,RISANKIZUMAB治疗导致肠炎和/或甲状腺炎的更大缓解.
- 观察到患者报告结果的有意义改善,并与瑞桑基祖马布治疗持续.
- 瑞桑基祖马布在PsA中提供了关键肌肉骨病变的潜在持续缓解.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
131
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
131
T Cell Types and Functions
1.0K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.0K
The JAK-STAT Signaling Pathway
8.8K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.8K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
158
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
158


